<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nonimmune hydrops fetalis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nonimmune hydrops fetalis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Nonimmune hydrops fetalis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Svena Julien, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Louise Wilkins-Haug, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph A Garcia-Prats, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynn L Simpson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hydrops fetalis refers to the presence of at least two abnormal fluid collections in the fetus, including fluid in serous cavities (eg, ascites, pleural effusions, pericardial effusions) and generalized skin edema. Nonimmune hydrops fetalis (NIHF) comprises the subgroup of cases not caused by red blood cell alloimmunization (eg, RhD, Kell). Multiple fetal anatomic and functional disorders can cause NIHF, which can be lethal.</p><p>This topic will review issues related to NIHF. Red blood cell alloimmunization is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6820.html" rel="external">"RhD alloimmunization in pregnancy: Overview"</a> and  <a class="medical medical_review" href="/z/d/html/7921.html" rel="external">"Management of non-RhD red blood cell alloantibodies during pregnancy"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>The prevalence of NIHF ranges from 1 in 1500 to 1 in 4000 births [<a href="#rid1">1-6</a>]. Wide variations in reported prevalence are due to differences in definitions, populations (eg, Southeast Asian populations have a high prevalence of alpha- and beta thalassemia [<a href="#rid7">7</a>]), thoroughness of evaluation, and whether late pregnancy terminations were included.</p><p>The widespread use of <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">anti-D immune globulin</a> dramatically decreased the prevalence of RhD alloimmunization and associated hydrops after 1968 when the drug became available. As a result, NIHF now accounts for &gt;90 percent of hydrops cases [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Dysregulation of the net fluid movement between the vascular and interstitial spaces leading to NIHF can be caused by fetal disorders with one or more of the following features [<a href="#rid8">8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Obstructed lymphatic drainage in the thoracic and abdominal cavities</p><p class="bulletIndent1"><span class="glyph">●</span>Increased capillary permeability</p><p class="bulletIndent1"><span class="glyph">●</span>Increased central venous pressure</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased osmotic pressure</p><p></p><p>However, the pathogenesis of NIHF is incompletely understood. Further investigation is needed to understand the complex interplay between fetal myocardial function, maintenance of intravascular volume, and neural and circulating plasma proteins and hormones, and to explain how each factor contributes to hydrops. Although the exchange of fluid between the plasma and the interstitium is determined by the hydrostatic and oncotic pressures in each compartment, actual capillary hemodynamics differ from that predicted by the Starling equation because the structure of the interstitial space and the capillary filtration barrier are much more complex than was once believed. (See  <a class="medical medical_review" href="/z/d/html/2309.html" rel="external">"Pathophysiology and etiology of edema in adults"</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL PRESENTATION AND FINDINGS</span></p><p class="headingAnchor" id="H600837149"><span class="h2">Presentation</span><span class="headingEndMark"> — </span>In asymptomatic pregnant patients, NIHF may be discovered incidentally during prenatal sonography performed for standard obstetric indications (eg, anatomic survey, fetal growth). In other cases, hydrops is discovered on prenatal sonography performed intermittently specifically to monitor fetuses known to be at risk for disorders associated with NIHF.</p><p>When hydrops is associated with polyhydramnios, NIHF may be discovered during a work-up for uterine size greater than dates. Rarely, hydrops is associated with the early onset of maternal preeclampsia (ie, Mirror syndrome) and NIHF may be discovered as part of the fetal evaluation of this disorder.</p><p class="headingAnchor" id="H600830836"><span class="h2">Fetal findings</span><span class="headingEndMark"> — </span>NIHF is defined by fetal findings. Two or more of the following findings should be present on ultrasound examination:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ascites</strong> – In its early stage, fetal ascites appears as a rim of echolucent fluid just inside the abdominal wall  (<a class="graphic graphic_diagnosticimage graphicRef62798" href="/z/d/graphic/62798.html" rel="external">image 1</a>) or surrounding the bladder or liver. If there is a large amount of ascites, the bowel may appear compressed in the central abdomen  (<a class="graphic graphic_diagnosticimage graphicRef56150" href="/z/d/graphic/56150.html" rel="external">image 2</a>), and its walls may be accentuated due to increased ultrasound transmission afforded by the excess intraabdominal fluid [<a href="#rid4">4,9</a>]. Pseudoascites  (<a class="graphic graphic_diagnosticimage graphicRef128014" href="/z/d/graphic/128014.html" rel="external">image 3</a>), which is a hypoechoic band consisting of abdominal wall muscles, should not be mistaken for ascites.</p><p></p><p class="bulletIndent1">Isolated fetal ascites can result from several disorders and is not considered hydrops since only one compartment is affected. In a systematic review, etiologies included genitourinary (24 percent), gastrointestinal (20 percent), viral or bacterial infection (9 percent), cardiac (9 percent), genetic disorders (8 percent), chylous ascites (6 percent), metabolic storage disorders (3 percent), other structural disorders (4 percent), other causes (4 percent), and idiopathic (13 percent) [<a href="#rid10">10</a>]. Approximately 6 percent of initial diagnosis of isolated ascites progressed to hydrops and 30 percent spontaneously resolved. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pleural effusions</strong> – Pleural effusions appear as a rim of hypoechoic fluid just inside the chest wall, outlining the lungs. The effusion may be unilateral or bilateral, and may compress the lung tissue  (<a class="graphic graphic_diagnosticimage graphicRef54321 graphicRef70095 graphicRef100755" href="/z/d/graphic/54321.html" rel="external">image 4A-C</a>). Persistent effusions that develop before 20 weeks of gestation may inhibit lung growth and development, resulting in pulmonary hypoplasia, which may be fatal in the neonatal period. A variety of techniques for prenatal diagnosis of severe pulmonary hypoplasia have been reported, but none are consistently reliable [<a href="#rid11">11</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pericardial effusion</strong> – A pericardial effusion appears as a rim of echolucent fluid surrounding the heart  (<a class="graphic graphic_diagnosticimage graphicRef53761" href="/z/d/graphic/53761.html" rel="external">image 5</a>) but may be difficult to visualize with standard two-dimensional images. It is important to not mistake physiologic pericardial fluid or the hypoechoic myocardium for an abnormal effusion. Using M-mode helps in measuring pericardial effusions accurately and differentiating between physiologic and pathologic pericardial fluid when the diagnosis is uncertain [<a href="#rid2">2</a>]. </p><p></p><p class="bulletIndent1">During second-trimester fetal ultrasonographic examination, pericardial fluid greater than 2 mm in thickness that increases on serial examinations suggests a pathologic etiology. Visualization of pericardial fluid up to 2 mm thick is common and should not be regarded as pathologic [<a href="#rid12">12</a>], and even fluid up to 7 mm thick may be benign [<a href="#rid13">13</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin edema </strong>– Generalized skin edema is a late sign of fetal hydrops  (<a class="graphic graphic_diagnosticimage graphicRef61425" href="/z/d/graphic/61425.html" rel="external">image 6</a>). Pathologic skin edema has been defined as subcutaneous tissue thickness &gt;5 mm; however, fat under the scalp or in the posterior nuchal region should not be mistaken for skin edema.</p><p></p><p>In addition, NIHF may be associated with polyhydramnios and placental thickening. However, these findings are not included in the fluid collections needed for diagnosis of hydrops.</p><p class="bulletIndent1"><span class="glyph">●</span>Polyhydramnios is defined as a single deepest pocket ≥8 cm or an amniotic fluid index ≥24 cm [<a href="#rid14">14</a>]. It is present in up to 75 percent of pregnancies complicated by NIHF. (See  <a class="medical medical_review" href="/z/d/html/6781.html" rel="external">"Polyhydramnios: Etiology, diagnosis, and management in singleton gestations", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In general, a placental thickness ≥4 cm in the second trimester and ≥6 cm in the third trimester is considered abnormal and should prompt further investigation [<a href="#rid15">15,16</a>]. In NIHF, placental thickening is likely due to intravillous edema. However, in patients with massive polyhydramnios, the excessive amniotic fluid can make the placenta appear thinned or compressed.</p><p></p><p class="headingAnchor" id="H600830844"><span class="h2">Maternal findings</span><span class="headingEndMark"> — </span>Patients carrying a hydropic fetus may have uterine size large for dates and may notice decreased fetal movement. Severe polyhydramnios may lead to shortness of breath, which may necessitate treatment or delivery. (See  <a class="medical medical_review" href="/z/d/html/6781.html" rel="external">"Polyhydramnios: Etiology, diagnosis, and management in singleton gestations", section on 'Management of polyhydramnios in singleton pregnancies'</a>.)</p><p>Although hydrops is a fetal condition, in some cases, there are associated maternal disorders, such as preeclampsia (Mirror syndrome) or theca lutein cysts [<a href="#rid17">17-21</a>]. </p><p class="headingAnchor" id="H6"><span class="h3">Mirror syndrome</span><span class="headingEndMark"> — </span>Mirror syndrome (also called Ballantynes syndrome) refers to a condition of generalized maternal edema, often with pulmonary involvement, that "mirrors" the edema of the hydropic fetus and placenta. Although usually associated with NIHF, it can also occur with immune-mediated hydrops. The pathogenesis has not been firmly established, but at least in some cases, the hydropic placenta increases production of soluble fms-like tyrosine kinase (sFlt1), which is an important mediator of maternal endothelial and vascular abnormalities in preeclampsia [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/z/d/html/6760.html" rel="external">"Preeclampsia: Pathogenesis"</a>.)</p><p>Mirror syndrome can occur any time during the antepartum period and may persist postpartum [<a href="#rid23">23</a>]. It may present with rapid weight gain, increasing peripheral edema, and progressive shortness of breath, or with a clinical presentation and course similar to preeclampsia with severe features. In contrast to preeclampsia, the maternal hematocrit is often low (hemodilution) rather than high (hemoconcentration), amniotic fluid volume is often high (polyhydramnios) rather than low (oligohydramnios), and the fetus always shows signs of hydrops [<a href="#rid24">24,25</a>]. In a systematic review of 12 reports of Mirror syndrome in 82 patients, common maternal signs were edema (62 percent), hypoalbuminemia (55 percent), anemia (39 percent), and new-onset hypertension (39 percent) [<a href="#rid26">26</a>]. Six studies (47 patients) reported maternal complications, such as postpartum hemorrhage (45 percent), hemorrhage requiring transfusion (19 percent), intensive care unit admission (13 percent), heart failure (11 percent), pulmonary edema (8.5 percent), and kidney dysfunction (8.5 percent). In 39 cases, perinatal outcomes included stillbirth (67 percent) and neonatal or infant death (26 percent). Overall survival among continued pregnancies was low (7.7 percent). (See  <a class="medical medical_review" href="/z/d/html/6781.html" rel="external">"Polyhydramnios: Etiology, diagnosis, and management in singleton gestations"</a> and  <a class="medical medical_review" href="/z/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis"</a>.)</p><p>Delivery is usually required to induce remission of maternal symptoms. In the review described above, maternal symptoms disappeared 4.8 to 13.5 days after delivery [<a href="#rid27">27</a>]. Interventions that result in reversal of fetal hydrops, including selective feticide of a hydropic twin, can also reverse the maternal disorder, thereby allowing prolongation of the pregnancy [<a href="#rid25">25,28-31</a>]. Spontaneous resolution of Mirror syndrome has also been described after spontaneous resolution of fetal hydrops related to parvovirus infection and after fetal death. Resolution is associated with a fall in sFlt1 [<a href="#rid32">32</a>].</p><p>However, prompt delivery is indicated, even in NIHF with a treatable etiology, because pregnant patients with severe features of preeclampsia can deteriorate rapidly. These decisions should be made on a case-by-case basis, taking into account the severity of the maternal condition, the severity of the fetal condition, and the potential for rapid resolution of hydrops.</p><p class="headingAnchor" id="H2921197521"><span class="h3">Theca lutein cysts</span><span class="headingEndMark"> — </span>Theca lutein cysts are luteinized follicle cysts that form as a result of overstimulation from high human chorionic gonadotropin (hCG) levels or extreme sensitivity to hCG. Theca lutein cysts associated with NIHF have been attributed to elevated hCG production from the hydropic placenta. </p><p class="headingAnchor" id="H7"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The prenatal diagnosis of hydrops fetalis is based on ultrasound examination that shows two or more of the following fetal findings (see <a class="local">'Fetal findings'</a> above) [<a href="#rid33">33</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Ascites</p><p class="bulletIndent1"><span class="glyph">●</span>Pleural effusion</p><p class="bulletIndent1"><span class="glyph">●</span>Pericardial effusion</p><p class="bulletIndent1"><span class="glyph">●</span>Generalized skin edema (skin thickness &gt;5 mm)</p><p></p><p class="headingAnchor" id="H600831234"><span class="h1">POSTDIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>An attempt to determine the etiology of the hydrops should be made at the time of diagnosis, since several etiologies can be confirmed or excluded based upon ultrasound findings. </p><p>The etiology can be determined prenatally or postnatally in 60 to 85 percent of cases [<a href="#rid34">34</a>]. The remaining cases are considered idiopathic (ie, no anatomic malformation detected prenatally or postnatally, no maternal red cell antibodies, middle cerebral artery (MCA) peak systolic velocity (PSV) &lt;1.5 multiples of the median (MoM); as well as no neonatal anemia, known monogenetic disorders, fetal tumors, or lysosomal diseases (LDs); as well as negative maternal infection screening [eg, cytomegalovirus, toxoplasmosis, syphilis, parvovirus B19], euploid fetal karyotype, and normal microarray). (See <a class="local">'Etiology and prenatal management of disorders associated with hydrops'</a> below.)</p><p class="headingAnchor" id="H600831290"><span class="h2">General approach</span><span class="headingEndMark"> — </span>Hydrops is associated with a broad spectrum of disorders. Prenatally, the key issues are to (1) identify those cases caused by disorders that are treatable in utero and (2) deliver the fetus when the benefits of prolonging pregnancy are exceeded by the risk of imminent fetal demise. Prenatally or postnatally, it is also important to identify disorders with a risk of recurrence in future pregnancies.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fetal survey and echocardiography</strong> – We perform a thorough sonographic evaluation of the fetus, placenta, umbilical cord, and amniotic fluid to look for causes of NIHF that can be diagnosed by imaging, such as major fetal or placental structural abnormalities, arrhythmias, and twin-to-twin transfusion syndrome.</p><p></p><p class="bulletIndent1">A fetal echocardiogram should also be performed as it may detect previously unrecognized cardiac abnormalities, which may be the etiology or a consequence of hydrops [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/6755.html" rel="external">"Congenital heart disease: Prenatal screening, diagnosis, and management"</a> and  <a class="medical medical_review" href="/z/d/html/6765.html" rel="external">"Fetal arrhythmias"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MCA-PSV</strong> – We perform Doppler assessment of the fetal MCA-PSV to screen for fetal anemia. An MCA-PSV ≥1.5 MoM for the gestational age is an accurate noninvasive tool for predicting moderate to severe fetal anemia of any etiology (ie, immune or nonimmune) [<a href="#rid35">35,36</a>]. (See  <a class="medical medical_review" href="/z/d/html/6802.html" rel="external">"RhD alloimmunization in pregnancy: Management", section on 'Assess for severe anemia using MCA-PSV in fetuses at risk'</a>.)</p><p></p><p class="bulletIndent1">If MCA-PSV is ≥1.5 MoM, we try to determine the cause of the anemia (eg, parvovirus B19 infection, alloimmunization, fetomaternal bleeding, hemoglobinopathy). (See <a class="local">'Anemia'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pedigree</strong> – If the cause for NIHF is not identified by these examinations, we obtain a detailed family history (three generation pedigree). A genetic counselor can be helpful in obtaining a thorough history. (See  <a class="medical medical_review" href="/z/d/html/103304.html" rel="external">"Genetic counseling: Family history interpretation and risk assessment"</a>.)</p><p></p><p class="bulletIndent1">The patient's ethnic background and personal and family history are reviewed to look for heritable disorders associated with hydrops, such as alpha thalassemia, metabolic disorders, and genetic syndromes. We ask about consanguinity since this increases the probability of a recessive disorder, some of which present with fetal hydrops.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection exposure</strong> – We also ask about recent exposure to individuals, particularly children, with an infection. Parvovirus B19 is the most common infectious etiology of hydrops, accounting for approximately 15 percent of cases [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/8281.html" rel="external">"Parvovirus B19 infection during pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory examination</strong> – We perform the following laboratory evaluation. The sequence is determined by the most likely diagnoses in a specific patient, cost, and invasiveness. Some tests are performed simultaneously, as the results of individual tests may not be available for several days to weeks, thus precluding sequential studies.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Complete blood count with red blood cell indices</strong> – A mean corpuscular volume (MCV) &lt;80 femtoliters (fL) in the absence of iron deficiency suggests thalassemia. The biological father's MCV should be determined. If both parents have MCV &lt;80 fL, additional studies are required to make a definitive diagnosis.</p><p></p><p class="bulletIndent2">Initially, hemoglobin analysis is performed either by high-performance liquid chromatography or isoelectric focusing to identify abnormal hemoglobins associated with thalassemia (eg, hemoglobin F, hemoglobin A2, hemoglobin H)  (<a class="graphic graphic_table graphicRef115337" href="/z/d/graphic/115337.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent2">If hemoglobin analysis suggests alpha thalassemia (eg, high percentage of hemoglobin Bart's), then DNA-based testing for alpha globin gene deletions is required to establish a diagnosis. (See  <a class="medical medical_review" href="/z/d/html/445.html" rel="external">"Hemoglobinopathy: Screening and counseling in the reproductive setting and fetal diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/13941.html" rel="external">"Methods for hemoglobin analysis and hemoglobinopathy testing", section on 'Patient with suspected thalassemia'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Blood type and antibody screen</strong> – A positive screen for antibodies directed against red blood cell antigens suggests immune-mediated fetal anemia. (See  <a class="medical medical_review" href="/z/d/html/6820.html" rel="external">"RhD alloimmunization in pregnancy: Overview"</a> and  <a class="medical medical_review" href="/z/d/html/7921.html" rel="external">"Management of non-RhD red blood cell alloantibodies during pregnancy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Kleihauer-Betke acid elution smear or flow cytometry</strong> to exclude the possibility of significant fetomaternal hemorrhage [<a href="#rid15">15,38</a>]. (See  <a class="medical medical_review" href="/z/d/html/6806.html" rel="external">"Spontaneous massive fetomaternal hemorrhage", section on 'Measuring the volume of FMH'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Serology </strong>–<strong> </strong>Maternal immunoglobulin M (IgM) and IgG serologies are obtained for the most common infectious causes of NIHF: parvovirus B19, cytomegalovirus, and toxoplasmosis.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Parvovirus B19 is the most common of these. Ultrasound findings include fetal anemia and myocardial dysfunction. (See  <a class="medical medical_review" href="/z/d/html/8281.html" rel="external">"Parvovirus B19 infection during pregnancy"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Cytomegalovirus infection is characterized by bilateral periventricular hyperechogenicities (calcifications), but these may not be seen until the late second trimester  (<a class="graphic graphic_diagnosticimage graphicRef54305" href="/z/d/graphic/54305.html" rel="external">image 7</a>). (See  <a class="medical medical_review" href="/z/d/html/4810.html" rel="external">"Cytomegalovirus infection in pregnancy", section on 'Fetal issues'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Toxoplasmosis is characterized by intracranial hyperechogenic foci or calcifications and cerebral ventricular dilation. (See  <a class="medical medical_review" href="/z/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy", section on 'Fetal infection'</a>.)</p><p></p><p class="bulletIndent2">Hydrops is also a characteristic finding of congenital syphilis; therefore, a treponemal or nontreponemal antibody test should be obtained if not recently performed as part of routine prenatal care. (See  <a class="medical medical_review" href="/z/d/html/4794.html" rel="external">"Syphilis in pregnancy", section on 'Serologic testing'</a>.)</p><p></p><p class="bulletIndent2">In asymptomatic pregnant patients, there is a low yield from serology for rubella, varicella, adenovirus, coxsackie virus, and other less common infectious agents. We obtain these tests if the patient's history, physical examination, or ultrasound findings suggest one of these infections. We also may obtain them as a last resort if no etiology for NIHF has been determined by other testing. We do not obtain serology for herpes simplex virus (HSV) unless the patient has a history of primary genital HSV prior to onset of NIHF. In these cases, we prefer to send polymerase chain reaction (PCR) of amniotic fluid and correlate with maternal serology.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Amniocentesis</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Karyotype/microarray</strong> – Fetuses with NIHF and structural abnormalities should undergo microarray on amniocytes as they are at high risk of having a chromosomal abnormality. In the absence of a structural abnormality, the frequency of an abnormality is lower, and the diagnostic performance of microarray does not appear to be significantly better than with conventional G-band karyotype [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Advanced genomic testing</strong> – If the microarray is normal, assessing genes for recognized pathogenic variants (genotyping), single gene sequencing, multiple gene sequencing or genotyping through panels, or testing for specific deletions or duplications can be performed as appropriate for the disorder(s) under consideration [<a href="#rid40">40</a>]. Some commercial laboratories offer targeted gene panels to analyze a group of genes implicated in NIHF, but the panels vary among laboratories and the yield of such testing is unclear. In a study of 127 fetuses with NIHF who underwent exome sequencing, the diagnostic yield was 29 percent and significantly higher than the 18 percent yield expected from a large NIHF-targeted gene panel [<a href="#rid41">41</a>]. Overall, targeted gene panels detected only 11 to 62 percent of the pathogenic variants detected by exome sequencing. Thus, exome sequencing as an initial genetic test can simplify workflow and result in cost savings compared with targeted panels followed by exome sequencing for nondiagnostic cases. As genomic testing becomes more complex (including the option of clinical exome sequencing), consultation with a genetic counselor or geneticist can help direct the appropriate test when a genetic etiology is suspected but standard testing is nondiagnostic. Appropriate pretest and posttest genetic counseling by a provider experienced in the complexities of genomic sequencing are recommended. (See  <a class="medical medical_review" href="/z/d/html/104101.html" rel="external">"Prenatal genetic evaluation of the fetus with anomalies or soft markers"</a>.)</p><p></p><p class="bulletIndent3">In a meta-analysis of 21 studies evaluating the incremental yield of next-generation sequencing over standard prenatal diagnostic testing (microarray, G-banded karyotype) in NIHF, the pooled incremental yields of exome sequencing in the overall group of NIHF (306 cases), isolated NIHF (109 cases), and NIHF associated with additional fetal structural anomalies (109 cases) were 29, 21, and 39 percent, respectively [<a href="#rid42">42</a>]. When a causative pathogenic variant was documented, the most common genetic disorders were: RASopathies (30.3 percent, 27 out of 89), primarily due to <em>PTPN11</em> variants (12 out of 27); musculoskeletal disorders (14.6 percent, 13 out of 89), primarily due to <em>RYR1</em> variants (5 out of 13); and inborn errors of metabolism (12.4 percent, 11 out of 89), primarily due to <em>GUSB</em> variants (5 out of 11). The incremental yield for causative pathogenic variants was similar regardless of severity of hydrops. Other types of disorders detected by exome sequencing include musculoskeletal disorders, lymphedema disorders, neurodevelopmental disorders, cardiovascular disorders, hematologic disorders, kidney disorders, ciliopathies, and overgrowth disorders.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Testing for infection</strong> – An infectious etiology for NIHF should be excluded by maternal serologic testing. If amniocentesis for genetic studies is performed before serologic findings are available, we obtain an additional 10 mL of amniotic fluid to send for PCR for cytomegalovirus, parvovirus B19, and toxoplasmosis [<a href="#rid1">1,43</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Amniotic fluid alpha-fetoprotein (AFP)</strong> – If congenital nephrotic syndrome of the Finnish type (Finnish nephrosis) is suspected because of enlarged, hyperechogenic kidneys and/or an elevated maternal serum AFP level, an amniotic fluid AFP level should be obtained and may be increased more than 10-fold.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Other tests</strong> – A 10 mL sample of amniotic fluid should also be frozen and stored in order to test for rare LDs [<a href="#rid44">44</a>] in the at-risk patient (consanguinity, previous family history, Ashkenazi Jewish or French Canadian descent) or after other investigations have been nondiagnostic [<a href="#rid9">9,45,46</a>]. Alternatively, cells can be cultured, frozen, and stored in case additional studies are required.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Paracentesis</strong> – If the diagnostic evaluation described above does not reveal the cause, a sample of fetal ascitic fluid can be aspirated and analyzed for cell count and cytology, cytoplasmic vacuoles in lymphocytes, total protein, beta-2-microglobulin, total IgM, gamma-glutamyl transpeptidase, aspartate aminotransferase, aminopeptidase M, and total alkaline phosphatase.</p><p></p><p class="bulletIndent2">One study reported lymphocytes accounted for over 80 percent of the cell population in cases of chylous ascites, vacuolated cells were observed in 100 percent of cases of storage diseases, low protein levels (&lt;10 g/L) were observed in 75 percent of cases of urinary and genitourinary origin, high digestive enzymes levels (eg, gamma-glutamyl transpeptidase, aminopeptidase M, intestinal alkaline phosphatase) were observed in 100 percent of cases of digestive origin, and high beta-2-microglobulin values (&gt;5 mg/L) were observed in 100 percent of infectious cases; however, there were ≤14 cases (hydrops or ascites alone) in each of these categories [<a href="#rid47">47</a>]. Prognosis and management depend on the etiology.</p><p></p><p class="headingAnchor" id="H8"><span class="h1">ETIOLOGY AND PRENATAL MANAGEMENT OF DISORDERS ASSOCIATED WITH HYDROPS</span><span class="headingEndMark"> — </span>Fetal disorders associated with NIHF are typically grouped into etiologic categories (eg, chromosomal, hematologic, cardiothoracic, neoplastic, etc). Many of these disorders are listed in the following table  (<a class="graphic graphic_table graphicRef70066" href="/z/d/graphic/70066.html" rel="external">table 2</a>). Many others have been described in case reports; a complete list is beyond the scope of this topic.</p><p>The proportion of hydrops cases attributable to each etiologic category depends, in part, on the gestational age at presentation. NIHF prior to 24 weeks of gestation is usually related to an aneuploidy, while cardiac, pulmonary, and infectious etiologies account for the majority of cases after 24 weeks [<a href="#rid48">48,49</a>].</p><p class="headingAnchor" id="H937251923"><span class="h2">Cardiovascular abnormalities</span><span class="headingEndMark"> — </span>Abnormalities of the cardiovascular system are responsible for as many as 40 percent of cases of NIHF [<a href="#rid50">50</a>]. Numerous cardiac lesions have been implicated  (<a class="graphic graphic_table graphicRef70066" href="/z/d/graphic/70066.html" rel="external">table 2</a>), the three major subgroups are structural anomalies, arrhythmias, and vascular abnormalities. NIHF associated with cardiovascular abnormalities tends to present in the third trimester [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H937251960"><span class="h3">Structural</span><span class="headingEndMark"> — </span>The most commonly encountered cardiac lesions associated with hydrops are atrioventricular septal defect, hypoplastic left and right heart, and isolated ventricular or atrial septal defects. Other less common anomalies include Tetralogy of Fallot and premature closure of the ductus arteriosus. Many of these lesions are also associated with aneuploidy. Fetal cardiac tumors (eg, rhabdomyomas, teratomas) are rare, but are often associated with hydrops, ventricular obstruction, and/or arrhythmia [<a href="#rid52">52</a>]. </p><p>Surgical resection of mediastinal/pericardial teratomas in utero is possible, with good results [<a href="#rid53">53</a>]. Fetal cardiac intervention is an investigational procedure that has been performed for severe aortic stenosis with evolving hypoplastic left heart syndrome (HLHS), pulmonary atresia with intact ventricular septum and evolving hypoplastic right heart syndrome, and HLHS with intact or highly restrictive atrial septum [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/z/d/html/4881.html" rel="external">"Cardiac tumors", section on 'Fetal and neonatal intrapericardial teratoma'</a>.)</p><p>However, most structural lesions are not amenable to in utero therapy and, in the setting of early-onset hydrops, the prognosis for these pregnancies is poor, with a mortality rate close to 100 percent [<a href="#rid55">55</a>]. Patients should be offered genetic counseling, as the recurrence risk of congenital cardiac defects is as high as 2 to 5 percent [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H937252008"><span class="h3">Arrhythmias</span><span class="headingEndMark"> — </span>Both tachyarrhythmias and bradyarrhythmias can lead to hydrops. The mechanism is believed to be high output cardiac failure with progressive venous congestion in the former and low cardiac output in the latter.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tachyarrhythmias</strong> – Tachyarrhythmias associated with NIHF include supraventricular tachycardia (most commonly), followed by atrial flutter, reentrant tachycardias (eg, Wolf-Parkinson-White syndrome), long QT, and ventricular tachycardia. Fetal tachyarrhythmias can often be treated by maternal administration of rate controlling agents; however, in cases of hydrops, disturbances in the placental transfer may render maternal therapy inadequate [<a href="#rid55">55,57</a>]. In such cases, the drugs can be administered directly to the fetus. (See  <a class="medical medical_review" href="/z/d/html/6765.html" rel="external">"Fetal arrhythmias", section on 'Tachyarrhythmias'</a>.)</p><p></p><p class="bulletIndent1">In pregnant patients with Graves' disease, fetal tachycardia, particularly in combination with goiter, advanced bone age, poor growth, or craniosynostosis, suggests fetal hyperthyroidism from transplacental passage of maternal thyroid-stimulating hormone receptor antibody. Cardiac failure and hydrops may occur with severe disease. Maternal treatment with <a class="drug drug_general" data-topicid="9830" href="/z/d/drug information/9830.html" rel="external">propylthiouracil</a> or <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a> is an effective transplacental treatment of affected fetuses. (See  <a class="medical medical_review" href="/z/d/html/7884.html" rel="external">"Hyperthyroidism during pregnancy: Treatment", section on 'Fetal or neonatal hyperthyroidism'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bradyarrhythmias</strong> – One-half of persistent bradyarrhythmias are caused by structural abnormalities [<a href="#rid57">57</a>]. Complex congenital lesions that affect the AV nodal region result in anatomic interruptions in the conduction system leading to atrioventricular dissociation and bradycardia. The other one-half of persistent bradyarrhythmias are related to maternal autoimmune disorders in which maternal IgG antibodies cross the placenta and cause direct damage to fetal bundle of His and Purkinje fibers. (See  <a class="medical medical_review" href="/z/d/html/6765.html" rel="external">"Fetal arrhythmias", section on 'Bradyarrhythmias'</a>.)</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Aneuploidy</span><span class="headingEndMark"> — </span>Aneuploidy is responsible for 7 to 16 percent of NIHF cases [<a href="#rid33">33</a>]. The most common aneuploidy associated with NIHF is monosomy X (Turner syndrome), which accounts for 42 to 67 percent of aneuploid cases [<a href="#rid58">58</a>]. Other aneuploidies associated with hydrops include trisomy 21 (23 to 30 percent of cases); trisomy 13, 18, and 12 (10 percent of cases); tetraploidy; triploidy; and, rarely, deletions and duplications [<a href="#rid50">50,58</a>]. NIHF related to aneuploidy typically presents in the first and second trimesters [<a href="#rid51">51</a>].</p><p>The mechanism for fluid accumulation in these fetuses may involve obstruction or incomplete formation of the lymphatic system in the neck or abdomen, leading to lymphatic dysplasia, which can be seen sonographically as lucency under the skin, rather than diffuse skin thickening. Other mechanisms include cardiac failure related to congenital heart disease (present in 15 to 25 percent of aneuploid fetuses) [<a href="#rid56">56</a>] and transient abnormal myelopoiesis, a congenital leukemia associated with trisomy 21 [<a href="#rid59">59</a>]. (See  <a class="medical medical_review" href="/z/d/html/447.html" rel="external">"Sonographic findings associated with fetal aneuploidy"</a>.)</p><p>The prognosis is generally poor, with a mortality rate approaching 100 percent [<a href="#rid56">56</a>]. Management of the pregnancy with an aneuploid fetus depends on the prognosis for the specific chromosomal anomaly and the severity of coexistent anomalies. In nonlethal aneuploidies, fetal and maternal surveillance for signs of decompensation and possible early delivery are warranted. (See <a class="local">'Pregnancy and delivery management'</a> below.)</p><p class="headingAnchor" id="H366112365"><span class="h2">Syndromes</span><span class="headingEndMark"> — </span>Syndromes account for 5 to 10 percent of NIHF [<a href="#rid60">60</a>]. NIHF can be considered syndromic based on molecular findings, gene sequencing, or phenotypic/clinical findings seen on ultrasound/physical examination/autopsy. </p><p>Many genetic syndromes have been associated with NIHF  (<a class="graphic graphic_table graphicRef70066" href="/z/d/graphic/70066.html" rel="external">table 2</a>), including Opitz-Frias hypertelorism hypospadias syndrome, Familial Nuchal Bleb, Noonan syndrome, acrocephalopolydactylous dysplasia (also known as Elejalde syndrome), thoracoabdominal syndrome, lymphedema distichiasis syndrome, lethal multiple pterygium syndrome, arthrogryposis multiplex congenita, congenital myotonic dystrophy, Pena Shokeir syndrome, Neu-Laxova syndrome, Miller-Dieker syndrome, and yellow nail syndrome [<a href="#rid61">61-64</a>]. </p><p>Some monogenic mutations associated with NIHF include <em>PSAT1</em>, <em>PTPN11</em>, <em>PIEZO1, CCBE1, EPHB4, FOXC2, FOXP3, SOX18, </em>and<em> ITGA9</em>, but many others have been reported in one or more case reports<em> </em>[<a href="#rid65">65</a>]. In a pregnancy loss/stillbirth database, lethal multiple pterygium syndrome accounted for 6 percent of all hydropic cases in the database [<a href="#rid66">66</a>]. A systematic review found that <em>PIEZO1</em> variants were reported in 10 percent of NIHF cases diagnosed by prenatal exome analysis, making it the most common monogenic cause of NIHF [<a href="#rid67">67</a>].</p><p class="headingAnchor" id="H937252930"><span class="h2">Anemia</span><span class="headingEndMark"> — </span>Severe fetal anemia accounts for 10 to 27 percent of hydrops [<a href="#rid50">50</a>]. It may be due to a variety of causes, including hemorrhage, hemolysis, defective red cell production, and production of abnormal hemoglobins. Specific conditions associated with fetal anemia are listed in the table  (<a class="graphic graphic_table graphicRef70066" href="/z/d/graphic/70066.html" rel="external">table 2</a>). The mechanism for hydrops is thought to be high output cardiac failure. </p><p>Hydrops is observed when the fetal hemoglobin is less than half the median value for gestational age [<a href="#rid35">35</a>]. In general terms, fetal anemia is most likely to result in hydrops when the hemoglobin concentration is ≤5 g/dL, which approximates a hematocrit &lt;30 percent. A presumptive diagnosis of moderate to severe fetal anemia is made by Doppler assessment of the fetal middle cerebral artery (MCA) peak systolic velocity (PSV) ≥1.5 multiples of the median (sensitivity and specificity for severe anemia 75.5 and 90.8 percent, respectively) and can be confirmed by obtaining a fetal blood sample by cordocentesis. Whether to perform cordocentesis, follow MCA-PSV serially, transfuse in utero, or deliver the fetus depends on the gestational age and cause of anemia.</p><p>The major causes of anemia can be determined as follows: </p><p class="bulletIndent1"><span class="glyph">●</span>Alloimmunization as a cause of fetal anemia is suggested by positive results on maternal screening for antibodies directed against red blood cell antigens and excluded by negative results. (See  <a class="medical medical_review" href="/z/d/html/6820.html" rel="external">"RhD alloimmunization in pregnancy: Overview"</a> and  <a class="medical medical_review" href="/z/d/html/7921.html" rel="external">"Management of non-RhD red blood cell alloantibodies during pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Parental mean corpuscular volume &lt;80 femtoliters in the absence of iron deficiency suggests alpha or beta thalassemia  (<a class="graphic graphic_table graphicRef115337" href="/z/d/graphic/115337.html" rel="external">table 1</a>). Further testing with hemoglobin analysis is indicated to establish a diagnosis  (<a class="graphic graphic_algorithm graphicRef100633" href="/z/d/graphic/100633.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/445.html" rel="external">"Hemoglobinopathy: Screening and counseling in the reproductive setting and fetal diagnosis"</a>.)</p><p></p><p class="bulletIndent1">Alpha thalassemia major is the most common cause of NIHF among Southeast Asian populations. Profound acidosis, hypoxia, and hydrops develop early in the midtrimester, followed by intrauterine fetal demise unless the fetus is serially transfused. (See  <a class="medical medical_review" href="/z/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)"</a> and  <a class="medical medical_review" href="/z/d/html/7090.html" rel="external">"Pathophysiology of thalassemia"</a> and  <a class="medical medical_review" href="/z/d/html/7131.html" rel="external">"Molecular genetics of the thalassemia syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anemia secondary to massive fetomaternal transfusion is diagnosed by Kleihauer-Betke smear or flow cytometry. Transfusion or delivery can be life-saving. (See  <a class="medical medical_review" href="/z/d/html/6806.html" rel="external">"Spontaneous massive fetomaternal hemorrhage"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Parvovirus B19 infection is an infectious etiology of anemia. The laboratory diagnosis of maternal infection relies primarily upon IgG and IgM antibody testing to determine preexisting immunity, acute infection, or susceptibility. Polymerase chain reaction testing on amniotic fluid is the method of choice to make the fetal diagnosis. Fetal infection and treatment are discussed in more detail below. (See <a class="local">'Infection'</a> below.)</p><p></p><p class="headingAnchor" id="H937253350"><span class="h2">Infection</span><span class="headingEndMark"> — </span>Infections are responsible for 5 to 10 percent of NIHF  (<a class="graphic graphic_table graphicRef70066" href="/z/d/graphic/70066.html" rel="external">table 2</a>) [<a href="#rid33">33,68</a>]. Parvovirus B19 is the most common infection associated with hydrops, followed by cytomegalovirus, toxoplasmosis, and syphilis. Not all fetuses with the infections in the table develop hydrops and causation has not been proven for all of the infections. In some cases, a causative organism may not be identified.</p><p>Sonographic signs (in addition to hydrops) that suggest in utero infection include calcifications of the brain, liver, or pericardium; microcephaly; cerebral ventriculomegaly; hepatosplenomegaly; and growth restriction.</p><p>The pathogenesis for hydrops related to infection is not well understood in most cases; parvovirus B19 is an exception. This virus attacks red blood cell progenitors, hepatocytes, and myocardial cells causing transient aplastic crisis, hepatitis, and myocarditis [<a href="#rid4">4,68-70</a>]. Since these processes are self-limited, the prognosis is generally good if the fetus is supported by intrauterine fetal transfusions until the disease remits. Platelet concentrates should also be available for transfusion since some fetuses may also be profoundly thrombocytopenic. (See  <a class="medical medical_review" href="/z/d/html/8281.html" rel="external">"Parvovirus B19 infection during pregnancy"</a>.)</p><p>In contrast, the development of hydrops in fetuses with most other infections reflects multisystem failure (eg, myocarditis leading to heart failure, liver involvement leading to hypoalbuminemia) and is a poor prognostic sign. Therapy, if available, is directed toward the infectious agents.</p><p class="headingAnchor" id="H937253698"><span class="h2">Thoracic and lymphatic abnormalities</span><span class="headingEndMark"> — </span>Thoracic abnormalities  (<a class="graphic graphic_table graphicRef70066" href="/z/d/graphic/70066.html" rel="external">table 2</a>) account for up to 10 percent of hydrops. These lesions can cause mediastinal shift and can increase intrathoracic pressure and can obstruct venous return to the heart, leading to peripheral venous congestion, or they may obstruct the lymphatic duct, resulting in lymphedema. Interference with fluid exchange between the lung and amniotic cavity may contribute to polyhydramnios.</p><p>Fetal pleural effusions may be isolated or associated with hydrops, which confers a worse prognosis [<a href="#rid71">71-74</a>]. They can be related to aneuploidy (such as trisomy 21 or Turner syndrome), structural malformations or tumors (eg, involving the heart, lungs, lymphatic system), congenital infection (eg, cytomegalovirus, parvovirus B19, toxoplasmosis), and genetic syndromes [<a href="#rid73">73</a>]. The most common thoracic masses associated with NIHF are congenital pulmonary airway malformation (CPAM, formerly known as congenital cystic adenomatoid malformation) and bronchopulmonary sequestration (see  <a class="medical medical_review" href="/z/d/html/14207.html" rel="external">"Congenital pulmonary airway malformation: Prenatal diagnosis and management"</a> and  <a class="medical medical_review" href="/z/d/html/13515.html" rel="external">"Bronchopulmonary sequestration: Prenatal diagnosis and management"</a>). Primary congenital pulmonary lymphangiectasis results from thoracic duct obstruction, while secondary congenital pulmonary lymphangiectasis is a consequence of thoracic masses or congenital heart defects or a component of a discrete syndrome [<a href="#rid75">75-77</a>]. Primary congenital pulmonary lymphangiectasis leads to hydrops by reducing venous return or cardiac tamponade and may be treated by pleuroamniotic shunting at midgestation to prevent pulmonary hypoplasia. Generalized lymphangiectasis syndrome results from systemic lymphatic vessel ectasia [<a href="#rid78">78</a>]. In this condition, subcutaneous and visceral lymphedema occurs concomitantly with chylothorax. Hydrops results from gastrointestinal protein loss, chylothorax, and diffuse lymphatic leak. </p><p>The overall prognosis of hydropic fetuses with congenital pulmonary lesions depends, in part, on the gestational age at the time pulmonary abnormalities developed. Persistent pleural effusions before 20 weeks of gestation can compromise lung growth and function and thus are a poor prognostic sign. The degree of pulmonary hypoplasia cannot be reliably determined sonographically [<a href="#rid11">11</a>]. Therapeutic issues include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Needle aspiration of pleural effusions is not recommended, except as a prelude to shunting, because the fluid usually reaccumulates within 48 hours [<a href="#rid5">5,79</a>]. If pleural fluid is obtained, the diagnosis of chylothorax is confirmed by a fetal pleural effusion cell count with &gt;80 percent lymphocytes in the absence of infection [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For fetuses with CPAM, a course of maternal <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">betamethasone</a> administration is a medical option and has become the first-line therapy at less than 32 weeks in hydropic fetuses or fetuses determined to be at risk for developing hydrops because of a CPAM volume ratio (CVR) &gt;1.6. The therapeutic mechanism for resolution of hydrops is unknown, but it may be related to steroid-induced accelerated lung maturation or mass involution. The course of betamethasone may also improve outcomes in the event of a preterm delivery. (See  <a class="medical medical_review" href="/z/d/html/14207.html" rel="external">"Congenital pulmonary airway malformation: Prenatal diagnosis and management", section on 'First-line therapy: Maternal betamethasone administration'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In fetuses with large pleural effusions (eg, hydrothorax, chylothorax), placement of a pleuroamniotic shunt may alleviate the increased intrathoracic pressure, thereby reducing the risk of pulmonary hypoplasia [<a href="#rid9">9,71,80,81</a>]. It may also reduce venous and lymphatic obstruction and allow hydrops to resolve. </p><p></p><p class="bulletIndent1">This approach is supported by systematic reviews that found the survival rate for fetuses with pleural effusion and hydrops who were shunted was significantly higher than for those who underwent expectant management (over 60 percent versus less than 25 percent survival, respectively) [<a href="#rid79">79,82</a>]. However, only uncontrolled observational data from case reports and small case series were available for review; no controlled trials have been performed. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Open fetal surgery has been performed for management of thoracic lesions potentially causing pulmonary hypoplasia or hydrops, but this type of intervention is investigational and only available at specialized centers [<a href="#rid50">50</a>]. One small study of pleurodesis in 45 hydropic fetuses reported it was less effective than shunting [<a href="#rid83">83</a>]. </p><p></p><p class="headingAnchor" id="H937254130"><span class="h2">Twin gestation</span><span class="headingEndMark"> — </span>In both monochorionic and dichorionic twins, hydrops may develop in one or both twins from any of the etiologies that affect singleton pregnancies described above.</p><p>In addition, monochorionic twin gestations are at risk for hydrops from three disorders unique to these twin pregnancies: twin-to-twin transfusion syndrome (TTTS), twin anemia-polycythemia sequence (TAPS), and twin reversed arterial perfusion (TRAP). Polyhydramnios/oligohydramnios sequence is the defining characteristic of TTTS. One or both twins may develop NIHF, but usually the recipient twin is affected because of hypervolemia and increased central venous pressure. Hydrops of the donor twin is a sign of advanced stage TAPS. In TRAP, the hydropic twin has no normal cardiac structures. Treatment of TTTS, TAPS, and TRAP involves in utero procedures (eg, ablation, cord ligation, reduction amniocentesis). Prenatal diagnosis and management are reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6789.html" rel="external">"Twin-twin transfusion syndrome: Screening, prevalence, pathophysiology, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6793.html" rel="external">"Twin-twin transfusion syndrome: Management and outcome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/130852.html" rel="external">"Twin anemia-polycythemia sequence (TAPS)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14205.html" rel="external">"Twin reversed arterial perfusion (TRAP) sequence"</a>.)</p><p></p><p class="headingAnchor" id="H937254223"><span class="h2">Genitourinary malformations</span><span class="headingEndMark"> — </span>Abnormalities of the genitourinary tract account for a very small proportion of NIHF. A rare disorder of renal function, congenital Finnish type nephrosis, leads to hypoproteinemia and NIHF from decreased colloid oncotic pressure. The combination of an elevated maternal serum alpha-fetoprotein level and enlarged hyperechogenic fetal kidneys suggests the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/6137.html" rel="external">"Congenital nephrotic syndrome", section on 'Congenital Nephrotic Syndrome of Finnish type'</a>.)</p><p>Urinary ascites has been associated with hydrops by an unknown mechanism.</p><p class="headingAnchor" id="H937254321"><span class="h2">Gastrointestinal malformations</span><span class="headingEndMark"> — </span>Anomalies of the gastrointestinal tract associated with NIHF are listed in the table  (<a class="graphic graphic_table graphicRef70066" href="/z/d/graphic/70066.html" rel="external">table 2</a>) [<a href="#rid50">50</a>]. Ascites and polyhydramnios are characteristically observed with these disorders. More widespread edema may be present when the fetus is aneuploid. The prognosis depends upon the fetal karyotype and the severity of any associated disorders (eg, cystic fibrosis).</p><p class="headingAnchor" id="H937254405"><span class="h2">Placental and umbilical cord lesions</span><span class="headingEndMark"> — </span>Fetal/placental vascular tumors can lead to NIHF due to high output heart failure from arteriovenous shunting. Large chorioangiomas of the placenta may lead to NIHF by this mechanism and can be difficult to treat. The risk increases with increasing size of the chorioangioma. For chorioangiomas ≥2, ≥4, ≥6, ≥8, ≥10 cm, the frequency of fetal hydrops was approximately 15, 16, 20, 28, and 52 percent, respectively, in a systematic review that was derived from case reports and limited by ascertainment bias [<a href="#rid84">84</a>]. Intrauterine embolization, endoscopic laser coagulation of the feeding vessels (when there is adequate distance between the tumor location and the cord insertion), and insertion of coils or plugs to diminish or eliminate flow in the chorioangioma have been successful in pilot studies, but complications such as fetal bleeding, exsanguination, and death have also occurred [<a href="#rid85">85-90</a>]. In the systematic review, 57 percent had resolution of hydrops or hyperdynamic circulation after treatment, but perinatal mortality occurred in 31 percent [<a href="#rid84">84</a>]<em>.</em></p><p>Cord lesions associated with NIHF include angiomyxoma, aneurysm, venous thrombosis, umbilical vein torsion, true knots, and amniotic bands [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/16277.html" rel="external">"Umbilical cord abnormalities: Prenatal diagnosis and management"</a>.)</p><p class="headingAnchor" id="H937254451"><span class="h2">Fetal tumors</span><span class="headingEndMark"> — </span>Fetal tumors and lesions that have been associated with NIHF include sacrococcygeal, mediastinal, or pharyngeal teratoma; neuroblastoma; and large hemangiomas. NIHF has also been associated with fetal tuberous sclerosis and fetal tumors obstructing the vena cava, portal vein, or femoral vessels. </p><p>Fetuses with these tumors and lesions may develop cardiac failure or hepatic failure, resulting in NIHF. Intervention, if possible, depends on the type of tumor. (See  <a class="medical medical_review" href="/z/d/html/5200.html" rel="external">"Sacrococcygeal teratoma", section on 'Prenatal detection'</a> and  <a class="medical medical_review" href="/z/d/html/16277.html" rel="external">"Umbilical cord abnormalities: Prenatal diagnosis and management"</a> and  <a class="medical medical_review" href="/z/d/html/6175.html" rel="external">"Tuberous sclerosis complex: Clinical features"</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Inborn errors of metabolism</span><span class="headingEndMark"> — </span>Inborn errors of metabolism comprise a heterogeneous group of autosomal recessive disorders that may present in the fetal period as NIHF; they account for 1 to 2 percent of cases [<a href="#rid33">33</a>]. In one study, the overall incidence of lysosomal disease (LD) was 5.2 percent of all NIHF cases tested for any LD, 17.4 percent in idiopathic NIHF cases, and 24.6 percent of idiopathic NIHF cases where a comprehensive LD workup was done [<a href="#rid91">91</a>]. There were 35 cases of LD, and the three most common LDs were mucopolysaccharidosis type VII, Gaucher disease, and GM1-gangliosidosis. In another series of 28 cases of LD, the most common disorders were galactosialidosis, sialic acid storage disease, mucopolysaccharidosis type VII, and Gaucher disease [<a href="#rid92">92</a>].</p><p>These rare genetic disorders are due to lack of specific enzymes necessary to process various metabolites within the lysosome in organs such as the brain, heart, liver, and kidneys. The pathogenesis of hydrops is likely related to congestion of abdominal viscera from accumulation of these metabolites, leading to hepatitis and other organ damage [<a href="#rid45">45</a>]; ultrasound often shows hepatomegaly, splenomegaly, or hepatosplenomegaly [<a href="#rid92">92</a>]. This process then leads to increased hydrostatic pressure, decreased oncotic pressure, and possibly cardiomyopathy and cardiac dysfunction [<a href="#rid93">93</a>]. Decreased erythropoiesis resulting in anemia may also play a role. </p><p>Panels for testing for some causative storage disorders are available in some laboratories. An attempt at prenatal diagnosis is an option with cases of recurrence within a pedigree or when NIHF occurs in a structurally normal fetus and no cause has been identified after a standard work-up [<a href="#rid33">33,91,94</a>].</p><p>There is no specific therapy in the antenatal period; in utero death usually occurs. It is important to make an accurate diagnosis postnatally and offer genetic counseling, as the risk of recurrence in a future pregnancy is as high as 1 in 4. (See  <a class="medical medical_review" href="/z/d/html/2936.html" rel="external">"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features"</a> and  <a class="medical medical_review" href="/z/d/html/17216.html" rel="external">"Inborn errors of metabolism: Identifying the specific disorder"</a> and  <a class="medical medical_review" href="/z/d/html/2930.html" rel="external">"Inborn errors of metabolism: Classification"</a>.)</p><p class="headingAnchor" id="H600832580"><span class="h2">Skeletal dysplasias</span><span class="headingEndMark"> — </span>Skeletal dysplasias associated with NIHF include achondroplasia, achondrogenesis, osteogenesis imperfecta, osteopetrosis, thanatophoric dysplasia, short-rib polydactyly syndrome, and asphyxiating thoracic dysplasia [<a href="#rid33">33</a>]. The mechanism may involve altered venous return, cardiac tamponade, or hepatic dysfunction with hypoproteinemia. Prenatal diagnosis is based on recognition of skeletal abnormalities. (See  <a class="medical medical_review" href="/z/d/html/14209.html" rel="external">"Approach to prenatal diagnosis of the lethal (life-limiting) skeletal dysplasias"</a> and  <a class="medical medical_review" href="/z/d/html/13551.html" rel="external">"Skeletal dysplasias: Approach to evaluation"</a>.) </p><p class="headingAnchor" id="H26"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>NIHF is associated with an overall perinatal mortality rate of 50 to 98 percent [<a href="#rid2">2,3,37,38,95-97</a>]. Among live born infants, mortality was 43 percent by one year of age in one large series [<a href="#rid6">6</a>]. Despite advances in fetal diagnosis and therapy, the mortality rate has not changed substantially in recent years.</p><p>Prognosis depends upon the etiology, the gestational age at onset, the gestational age at birth, and whether pleural effusions are present. In general, the earlier hydrops occurs, the poorer the prognosis. In particular, pleural effusions and polyhydramnios prior to 20 weeks of gestation are poor prognostic signs because of increased risks of pulmonary hypoplasia and preterm prelabor rupture of membranes/preterm birth. On the other hand, absence of aneuploidy and absence of major structural abnormalities confer a better prognosis [<a href="#rid43">43,98</a>].</p><p class="headingAnchor" id="H600834741"><span class="h1">PREGNANCY AND DELIVERY MANAGEMENT</span></p><p class="headingAnchor" id="H910825804"><span class="h2">Counseling and planning</span><span class="headingEndMark"> — </span>Pregnancy counseling and management are guided by the etiology and severity of NIHF and whether it can be treated successfully. </p><p class="bulletIndent1"><span class="glyph">●</span>When a specific etiology is known or suspected, antenatal consultation with relevant subspecialty services is advisable and may help to guide decisions about the appropriate extent of fetal monitoring and intervention. Delivery of potentially viable neonates should occur at a tertiary care center with coordination of the obstetric, maternal-fetal medicine, neonatal, and pediatric subspecialty teams. </p><p></p><p class="bulletIndent1">Conditions amenable to fetal therapy often require urgent treatment, which may necessitate referral to a specialized center. Counseling should include a discussion of the potential risks and benefits of the available interventions versus expectant management, taking into account the severity of the underlying condition and the anticipated response to the intervention [<a href="#rid33">33</a>]. </p><p></p><p class="bulletIndent1">For cases with a lethal prognosis, pregnancy termination or postnatal comfort (palliative) care are options. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When the etiology is not known and the prognosis is uncertain, options include fetal monitoring with active intervention if there is fetal deterioration and parental support with no fetal intervention. Pregnancy termination is also an option.</p><p></p><p class="headingAnchor" id="H1759556923"><span class="h2">Maternal and fetal monitoring</span><span class="headingEndMark"> — </span>Maternal blood pressure and lymphedema should be monitored at least weekly for development of Mirror syndrome, as prompt delivery is usually indicated if it develops. (See <a class="local">'Mirror syndrome'</a> above.) </p><p>In the absence of a lethal etiology of NIHF, antenatal fetal surveillance is generally performed because of the high risk of fetal death and the possibility that early delivery will be beneficial. We perform nonstress testing or biophysical profile testing at least weekly, with delivery if there is evidence of fetal decompensation at a viable gestational age. </p><p>In addition, we perform Doppler assessment of the umbilical vein as development of umbilical venous pulsations in hydropic fetuses is an ominous finding associated with demise in over 70 percent of patients [<a href="#rid99">99</a>]. Serial Doppler velocimetry of the middle cerebral artery is not useful in the absence of suspected fetal anemia and Doppler velocimetry of the umbilical artery is not useful in the absence of fetal growth restriction (either abdominal circumference or estimated fetal weight &lt;10<sup>th</sup> percentile).</p><p>Antepartum corticosteroid therapy is indicated if the underlying etiology of the hydrops is not believed to be lethal and if preterm intervention is planned should deterioration of the fetal condition occur [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/6796.html" rel="external">"Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery"</a>.)</p><p class="headingAnchor" id="H2641215236"><span class="h2">Delivery</span><span class="headingEndMark"> — </span>Spontaneous or indicated preterm birth is common, occurring in 66 percent of pregnancies [<a href="#rid100">100</a>]. Based on expert opinion, new-onset or worsening NIHF in a pregnancy that has reached 34+0 weeks is a reasonable indication for delivery, although care should be individualized [<a href="#rid33">33</a>]. In the absence of a known lethal anomaly, maternal or fetal deterioration, or other indication for earlier intervention, we suggest delivery at 37+0 to 38+0 weeks. Preterm delivery &lt;34+0 weeks is a poor prognostic factor [<a href="#rid101">101</a>]. </p><p>If neonatal intervention will be withheld because of the poor prognosis, vaginal birth is preferred. Cesarean birth is performed for routine obstetric indications and is commonly required because delivery is often prompted by a deterioration in the fetal condition antepartum or the high frequency of nonreassuring intrapartum fetal heart rate patterns. Dystocia during delivery is also a concern and increases the risk of birth trauma regardless of mode of delivery. Ultrasound-guided percutaneous in utero needle aspiration of a large collection of ascites prior to delivery may reduce the risk of dystocia and facilitate neonatal resuscitation. </p><p>After delivery of the neonate, the mother is at increased risk for retained placenta and postpartum hemorrhage. (See  <a class="medical medical_review" href="/z/d/html/15333.html" rel="external">"Retained placenta after vaginal birth"</a> and  <a class="medical medical_review" href="/z/d/html/6710.html" rel="external">"Overview of postpartum hemorrhage"</a>.)</p><p class="headingAnchor" id="H2371179589"><span class="h3">Ex utero intrapartum therapy (EXIT)</span><span class="headingEndMark"> — </span>Congenital cardiac and thoracic abnormalities that result in NIHF very commonly result in rapid declines in pulmonary and/or cardiac function in the neonatal period that require immediate intervention. Depending on the etiology of NIHF, specific interventions to support the neonate may be indicated at delivery. </p><p>For example, a fetus with a large pulmonary lesion, mediastinal shift, and hydrops may benefit from ex utero intrapartum therapy (EXIT) performed at cesarean delivery [<a href="#rid102">102</a>]. In EXIT, the fetus is partially delivered and intubated prior to clamping the umbilical cord. Alternatively, uteroplacental blood flow and gas exchange are maintained by using inhalational agents to provide uterine relaxation and amnioinfusion to maintain uterine volume. This provides a multidisciplinary team sufficient time to initiate extracorporeal membrane oxygenation (EXIT to ECMO) to stabilize the neonate, thus allowing for a more controlled surgery by the pediatric surgical teams at a later time and place. However, the benefit of this approach is controversial and it is associated with increased maternal bleeding and need for transfusion [<a href="#rid103">103,104</a>].</p><p class="headingAnchor" id="H3571286734"><span class="h2">Stillborns</span><span class="headingEndMark"> — </span>We recommend autopsy in all cases of fetal death or pregnancy termination associated with NIHF. Consultation with a medical geneticist is also advisable. Storage of amniotic fluid and/or fetal cells has been suggested for future genetic testing [<a href="#rid105">105</a>]. (See  <a class="medical medical_review" href="/z/d/html/5402.html" rel="external">"Stillbirth: Maternal and fetal evaluation"</a>.)</p><p class="headingAnchor" id="H2905468553"><span class="h1">NEWBORN CARE</span><span class="headingEndMark"> — </span>Management of the newborn is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5027.html" rel="external">"Nonimmune hydrops fetalis in the neonate: Causes, presentation, and overview of neonatal management"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">RECURRENCE RISK</span><span class="headingEndMark"> — </span>The risk of recurrent NIHF depends upon the underlying etiology; therefore, every effort should be made to determine the cause. If hydrops was related to an anatomical variant (eg, congenital heart disease), the recurrence risk is minimal when the anatomic variant is not identified in the subsequent pregnancy. Hydrops related to a specific viral exposure (eg, parvovirus B19) should not recur because the mother will have developed immunity. By contrast, the risk of recurrent NIHF can be high when hydrops has a genetic basis, such as in alpha thalassemia. </p><p>As noted above, the clinician cannot always determine the etiology of fetal hydrops. Genetic consultation can be useful in these cases as the quality of information from genetic testing continues to evolve. Exome sequencing may identify an inherited autosomal dominant pathogenic variant that was not suspected initially as the cause of recurrent unexplained NIHF because the parental phenotype was mild and unrecognized [<a href="#rid106">106</a>]. Similarly, trio exome sequencing may identify rare autosomal recessive pathogenic variants as the cause of recurrent unexplained NIHF in consanguineous couples. In cases where no cause is found, the likelihood of recurrent hydrops is low [<a href="#rid107">107-109</a>]. However, since the risk of recurrence is not zero, a midtrimester sonogram to evaluate for signs of hydrops in subsequent gestations is reasonable. </p><p class="headingAnchor" id="H28"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Hydrops fetalis refers to two or more abnormal fluid collections in fetal soft tissues and serous cavities. Nonimmune hydrops fetalis (NIHF) comprises the subgroup of cases not caused by red blood cell alloimmunization (eg, RhD, Kell). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical findings and diagnosis</strong> – The diagnosis of hydrops is based on the presence of two or more of the following findings on ultrasound examination: pleural effusion, pericardial effusion, ascites, generalized skin edema &gt;5 mm. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients carrying a hydropic fetus may have uterine size large for dates and may notice decreased fetal movement, both issues often related to associated polyhydramnios. Although hydrops is a fetal condition, in many cases there are associated maternal findings, such as generalized edema with or without preeclampsia (ie, Mirror syndrome). (See <a class="local">'Maternal findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postdiagnostic evaluation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hydrops is associated with a broad spectrum of diseases, including aneuploidy, structural abnormalities, metabolic disorders, anemia, and infection  (<a class="graphic graphic_table graphicRef70066" href="/z/d/graphic/70066.html" rel="external">table 2</a>). An attempt to determine the etiology should be made at the time of diagnosis, since several etiologies can be confirmed or excluded based upon ultrasound findings. The cause of hydrops can be determined prenatally or postnatally in 60 to 85 percent of cases. (See <a class="local">'Etiology and prenatal management of disorders associated with hydrops'</a> above and <a class="local">'Postdiagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The goals are to (1) identify those cases caused by disorders that are treatable in utero and (2) deliver the fetus when the benefits of prolonging pregnancy are outweighed by the risk of fetal demise or risk of maternal decompensation. Prenatally or postnatally, it is important to identify disorders with a risk of recurrence in future pregnancies. Our approach to prenatal diagnosis is illustrated in the algorithm  (<a class="graphic graphic_algorithm graphicRef100483" href="/z/d/graphic/100483.html" rel="external">algorithm 2</a>). (See <a class="local">'General approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – The presence of hydrops is a poor prognostic indicator for perinatal survival (see <a class="local">'Prognosis'</a> above). Management and intervention are dictated by the underlying disease process and the gestational age at detection. Fetal anemia, fetal arrhythmias, and complications of monochorionic twin pregnancy are potentially amenable to in utero intervention. (See <a class="local">'Arrhythmias'</a> above and <a class="local">'Anemia'</a> above and <a class="local">'Twin gestation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy management</strong> – Maternal-fetal medicine specialists and neonatologists should be involved in the management of these pregnancies. Close surveillance of maternal status is important because of increased risks of Mirror syndrome. In addition (see <a class="local">'Pregnancy and delivery management'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>NSTs and BPPs</strong> – In the absence of a lethal etiology of NIHF, we perform nonstress testing or biophysical profile testing at least weekly, with delivery if there is evidence of fetal decompensation at a viable gestational age. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Umbilical vein Doppler</strong> – We perform Doppler assessment of the umbilical vein as development of umbilical venous pulsations in hydropic fetuses is an ominous finding associated with demise in over 70 percent of patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antenatal corticosteroids</strong> – Antenatal corticosteroid (ACS) therapy is indicated if the gestational age is between 24 and 34 weeks, the underlying etiology of the hydrops is not believed to be lethal, and if intervention is planned should deterioration of the fetal condition occur. Some providers administer a course of ACS after 34 weeks of gestation in patients at high risk for late preterm birth. (See  <a class="medical medical_review" href="/z/d/html/6796.html" rel="external">"Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Timing of delivery</strong> – Preterm birth &lt;34 weeks is a poor prognostic factor and should be avoided in the absence of deterioration in maternal or fetal status. New onset or worsening of NIHF in a pregnancy that has reached 34 weeks is a reasonable indication for delivery, although care should be individualized. However, in the absence of clinical deterioration or other indication for earlier intervention, we suggest delivery at 37 to 38 weeks.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Route of delivery</strong> – Vaginal birth is preferred if neonatal intervention will be withheld because of the poor prognosis. Cesarean birth is performed for routine obstetric indications; however, it is commonly required because delivery is often prompted by a deterioration in the fetal condition antepartum and because of the high frequency of category II and III fetal heart rate patterns intrapartum. </p><p></p><p class="bulletIndent2">Ultrasound guided percutaneous in utero needle aspiration of a large collection of pleural fluid and/or ascites prior to delivery may reduce the risk of dystocia and facilitate neonatal resuscitation. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of recurrence</strong> – The risk of recurrent NIHF depends upon the underlying etiology. (See <a class="local">'Recurrence risk'</a> above.)</p><p></p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sohan K, Carroll SG, De La Fuente S, et al. Analysis of outcome in hydrops fetalis in relation to gestational age at diagnosis, cause and treatment. Acta Obstet Gynecol Scand 2001; 80:726.</a></li><li><a class="nounderline abstract_t">Carlson DE, Platt LD, Medearis AL, Horenstein J. Prognostic indicators of the resolution of nonimmune hydrops fetalis and survival of the fetus. Am J Obstet Gynecol 1990; 163:1785.</a></li><li><a class="nounderline abstract_t">Castillo RA, Devoe LD, Hadi HA, et al. Nonimmune hydrops fetalis: clinical experience and factors related to a poor outcome. Am J Obstet Gynecol 1986; 155:812.</a></li><li class="breakAll">Callen P. Ultrasonography in Obstetrics and Gynecology, 4th ed, WB Saunders, Philadelphia 2000.</li><li><a class="nounderline abstract_t">Anandakumar C, Biswas A, Wong YC, et al. Management of non-immune hydrops: 8 years' experience. Ultrasound Obstet Gynecol 1996; 8:196.</a></li><li><a class="nounderline abstract_t">Steurer MA, Peyvandi S, Baer RJ, et al. Epidemiology of Live Born Infants with Nonimmune Hydrops Fetalis-Insights from a Population-Based Dataset. J Pediatr 2017; 187:182.</a></li><li><a class="nounderline abstract_t">Fucharoen S, Winichagoon P. Thalassemia in SouthEast Asia: problems and strategy for prevention and control. Southeast Asian J Trop Med Public Health 1992; 23:647.</a></li><li><a class="nounderline abstract_t">Bellini C, Hennekam RC. Non-immune hydrops fetalis: a short review of etiology and pathophysiology. Am J Med Genet A 2012; 158A:597.</a></li><li><a class="nounderline abstract_t">Jones DC. Nonimmune fetal hydrops: diagnosis and obstetrical management. Semin Perinatol 1995; 19:447.</a></li><li><a class="nounderline abstract_t">Horgan R, Youssef JA, Levy AT, et al. Etiology and Outcome of Isolated Fetal Ascites: A Systematic Review. Obstet Gynecol 2021; 138:897.</a></li><li><a class="nounderline abstract_t">Vergani P. Prenatal diagnosis of pulmonary hypoplasia. Curr Opin Obstet Gynecol 2012; 24:89.</a></li><li><a class="nounderline abstract_t">Dizon-Townson DS, Dildy GA, Clark SL. A prospective evaluation of fetal pericardial fluid in 506 second-trimester low-risk pregnancies. Obstet Gynecol 1997; 90:958.</a></li><li><a class="nounderline abstract_t">Di Salvo DN, Brown DL, Doubilet PM, et al. Clinical significance of isolated fetal pericardial effusion. J Ultrasound Med 1994; 13:291.</a></li><li><a class="nounderline abstract_t">Society for Maternal-Fetal Medicine (SMFM). Electronic address: <span class="__cf_email__" data-cfemail="ed9d988f9ead9e808b80c3829f8a">[email protected]</span>, Dashe JS, Pressman EK, Hibbard JU. SMFM Consult Series #46: Evaluation and management of polyhydramnios. Am J Obstet Gynecol 2018; 219:B2.</a></li><li><a class="nounderline abstract_t">Arcasoy MO, Gallagher PG. Hematologic disorders and nonimmune hydrops fetalis. Semin Perinatol 1995; 19:502.</a></li><li><a class="nounderline abstract_t">Chitkara U, Wilkins I, Lynch L, et al. The role of sonography in assessing severity of fetal anemia in Rh- and Kell-isoimmunized pregnancies. Obstet Gynecol 1988; 71:393.</a></li><li><a class="nounderline abstract_t">Fleming P, McLeary RD. Nonimmunologic fetal hydrops wtih theca lutein cysts. Radiology 1981; 141:169.</a></li><li><a class="nounderline abstract_t">Miller PD, Smith BC, Marinoff DN. Theca-lutein ovarian cysts associated with homozygous alpha-thalassemia. Am J Obstet Gynecol 1987; 157:912.</a></li><li><a class="nounderline abstract_t">Hatjis CG. Nonimmunologic fetal hydrops associated with hyperreactio luteinalis. Obstet Gynecol 1985; 65:11S.</a></li><li><a class="nounderline abstract_t">Frates MC, Feinberg BB. Early prenatal sonographic diagnosis of twin triploid gestation presenting with fetal hydrops and theca-lutein ovarian cysts. J Clin Ultrasound 2000; 28:137.</a></li><li><a class="nounderline abstract_t">Takeda T, Minekawa R, Makino M, et al. Hyperreactio luteinalis associated with severe twin-to-twin transfusion syndrome. Gynecol Obstet Invest 2002; 53:243.</a></li><li><a class="nounderline abstract_t">Stepan H, Faber R. Elevated sFlt1 level and preeclampsia with parvovirus-induced hydrops. N Engl J Med 2006; 354:1857.</a></li><li><a class="nounderline abstract_t">Nakamura K, Itoh H, Sagawa N, et al. A case of peripartum cardiomyopathy with a transient increase of plasma interleukin-6 concentration occurred following mirror syndrome. J Perinat Med 2002; 30:426.</a></li><li><a class="nounderline abstract_t">Vidaeff AC, Pschirrer ER, Mastrobattista JM, et al. Mirror syndrome. A case report. J Reprod Med 2002; 47:770.</a></li><li><a class="nounderline abstract_t">van Selm M, Kanhai HH, Gravenhorst JB. Maternal hydrops syndrome: a review. Obstet Gynecol Surv 1991; 46:785.</a></li><li><a class="nounderline abstract_t">Biswas S, Gomez J, Horgan R, et al. Mirror syndrome: a systematic literature review. Am J Obstet Gynecol MFM 2023; 5:101067.</a></li><li><a class="nounderline abstract_t">Braun T, Brauer M, Fuchs I, et al. Mirror syndrome: a systematic review of fetal associated conditions, maternal presentation and perinatal outcome. Fetal Diagn Ther 2010; 27:191.</a></li><li><a class="nounderline abstract_t">Heyborne KD, Chism DM. Reversal of Ballantyne syndrome by selective second-trimester fetal termination. A case report. J Reprod Med 2000; 45:360.</a></li><li><a class="nounderline abstract_t">Pirhonen JP, Hartgill TW. Spontaneous reversal of mirror syndrome in a twin pregnancy after a single fetal death. Eur J Obstet Gynecol Reprod Biol 2004; 116:106.</a></li><li><a class="nounderline abstract_t">Livingston JC, Malik KM, Crombleholme TM, et al. Mirror syndrome: a novel approach to therapy with fetal peritoneal-amniotic shunt. Obstet Gynecol 2007; 110:540.</a></li><li><a class="nounderline abstract_t">Okby R, Mazor M, Erez O, et al. Reversal of mirror syndrome after selective feticide of a hydropic fetus in a dichorionic diamniotic twin pregnancy. J Ultrasound Med 2015; 34:351.</a></li><li><a class="nounderline abstract_t">Goa S, Mimura K, Kakigano A, et al. Normalisation of angiogenic imbalance after intra-uterine transfusion for mirror syndrome caused by parvovirus B19. Fetal Diagn Ther 2013; 34:176.</a></li><li><a class="nounderline abstract_t">Society for Maternal-Fetal Medicine (SMFM), Norton ME, Chauhan SP, Dashe JS. Society for maternal-fetal medicine (SMFM) clinical guideline #7: nonimmune hydrops fetalis. Am J Obstet Gynecol 2015; 212:127.</a></li><li><a class="nounderline abstract_t">Bellini C, Hennekam RC, Fulcheri E, et al. Etiology of nonimmune hydrops fetalis: a systematic review. Am J Med Genet A 2009; 149A:844.</a></li><li><a class="nounderline abstract_t">Mari G, Deter RL, Carpenter RL, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. N Engl J Med 2000; 342:9.</a></li><li><a class="nounderline abstract_t">Borna S, Mirzaie F, Hanthoush-Zadeh S, et al. Middle cerebral artery peak systolic velocity and ductus venosus velocity in the investigation of nonimmune hydrops. J Clin Ultrasound 2009; 37:385.</a></li><li><a class="nounderline abstract_t">Ismail KM, Martin WL, Ghosh S, et al. Etiology and outcome of hydrops fetalis. J Matern Fetal Med 2001; 10:175.</a></li><li><a class="nounderline abstract_t">Graves GR, Baskett TF. Nonimmune hydrops fetalis: antenatal diagnosis and management. Am J Obstet Gynecol 1984; 148:563.</a></li><li><a class="nounderline abstract_t">Mardy AH, Rangwala N, Hernandez-Cruz Y, et al. Utility of chromosomal microarray for diagnosis in cases of nonimmune hydrops fetalis. Prenat Diagn 2020; 40:492.</a></li><li><a class="nounderline abstract_t">Mardy AH, Chetty SP, Norton ME, Sparks TN. A system-based approach to the genetic etiologies of non-immune hydrops fetalis. Prenat Diagn 2019; 39:732.</a></li><li><a class="nounderline abstract_t">Norton ME, Ziffle JV, Lianoglou BR, et al. Exome sequencing vs targeted gene panels for the evaluation of nonimmune hydrops fetalis. Am J Obstet Gynecol 2022; 226:128.e1.</a></li><li><a class="nounderline abstract_t">Mone F, Eberhardt RY, Hurles ME, et al. Fetal hydrops and the Incremental yield of Next-generation sequencing over standard prenatal Diagnostic testing (FIND) study: prospective cohort study and meta-analysis. Ultrasound Obstet Gynecol 2021; 58:509.</a></li><li><a class="nounderline abstract_t">McCoy MC, Katz VL, Gould N, Kuller JA. Non-immune hydrops after 20 weeks' gestation: review of 10 years' experience with suggestions for management. Obstet Gynecol 1995; 85:578.</a></li><li><a class="nounderline abstract_t">Verma J, Thomas DC, Sharma S, et al. Inherited metabolic disorders: prenatal diagnosis of lysosomal storage disorders. Prenat Diagn 2015; 35:1137.</a></li><li><a class="nounderline abstract_t">Molyneux AJ, Blair E, Coleman N, Daish P. Mucopolysaccharidosis type VII associated with hydrops fetalis: histopathological and ultrastructural features with genetic implications. J Clin Pathol 1997; 50:252.</a></li><li><a class="nounderline abstract_t">Burin MG, Scholz AP, Gus R, et al. Investigation of lysosomal storage diseases in nonimmune hydrops fetalis. Prenat Diagn 2004; 24:653.</a></li><li><a class="nounderline abstract_t">Dreux S, Salomon LJ, Rosenblatt J, et al. Biochemical analysis of ascites fluid as an aid to etiological diagnosis: a series of 100 cases of nonimmune fetal ascites. Prenat Diagn 2015; 35:214.</a></li><li><a class="nounderline abstract_t">Kessel I, Makhoul IR, Sujov P. Congenital hypothyroidism and nonimmune hydrops fetalis: associated? Pediatrics 1999; 103:E9.</a></li><li><a class="nounderline abstract_t">Lallemand AV, Doco-Fenzy M, Gaillard DA. Investigation of nonimmune hydrops fetalis: multidisciplinary studies are necessary for diagnosis--review of 94 cases. Pediatr Dev Pathol 1999; 2:432.</a></li><li><a class="nounderline abstract_t">Forouzan I. Hydrops fetalis: recent advances. Obstet Gynecol Surv 1997; 52:130.</a></li><li><a class="nounderline abstract_t">Sileo FG, Kulkarni A, Branescu I, et al. Non-immune fetal hydrops: etiology and outcome according to gestational age at diagnosis. Ultrasound Obstet Gynecol 2020; 56:416.</a></li><li><a class="nounderline abstract_t">Yinon Y, Chitayat D, Blaser S, et al. Fetal cardiac tumors: a single-center experience of 40 cases. Prenat Diagn 2010; 30:941.</a></li><li><a class="nounderline abstract_t">Rychik J, Khalek N, Gaynor JW, et al. Fetal intrapericardial teratoma: natural history and management including successful in utero surgery. Am J Obstet Gynecol 2016; 215:780.e1.</a></li><li><a class="nounderline abstract_t">Freud LR, Tworetzky W. Fetal interventions for congenital heart disease. Curr Opin Pediatr 2016; 28:156.</a></li><li><a class="nounderline abstract_t">Crawford DC, Chita SK, Allan LD. Prenatal detection of congenital heart disease: factors affecting obstetric management and survival. Am J Obstet Gynecol 1988; 159:352.</a></li><li class="breakAll">Hess DB, Hess LW. Fetal Echocardiography, Appleton and Lange, Stamford, CT 1999.</li><li><a class="nounderline abstract_t">Copel JA, Friedman AH, Kleinman CS. Management of fetal cardiac arrhythmias. Obstet Gynecol Clin North Am 1997; 24:201.</a></li><li><a class="nounderline abstract_t">Machin GA. Hydrops revisited: literature review of 1,414 cases published in the 1980s. Am J Med Genet 1989; 34:366.</a></li><li><a class="nounderline abstract_t">Malin GL, Kilby MD, Velangi M. Transient abnormal myelopoiesis associated with Down syndrome presenting as severe hydrops fetalis: a case report. Fetal Diagn Ther 2010; 27:171.</a></li><li><a class="nounderline abstract_t">Laterre M, Bernard P, Vikkula M, Sznajer Y. Improved diagnosis in nonimmune hydrops fetalis using a standardized algorithm. Prenat Diagn 2018; 38:337.</a></li><li><a class="nounderline abstract_t">Bieber FR, Petres RE, Bieber JM, Nance WE. Prenatal detection of a familial nuchal bleb simulating encephalocele. Birth Defects Orig Artic Ser 1979; 15:51.</a></li><li><a class="nounderline abstract_t">Thornton CM, Stewart F. Elejalde syndrome: a case report. Am J Med Genet 1997; 69:406.</a></li><li><a class="nounderline abstract_t">Grethel EJ, Hornberger LK, Farmer DL. Prenatal and postnatal management of a patient with pentalogy of Cantrell and left ventricular aneurysm. A case report and literature review. Fetal Diagn Ther 2007; 22:269.</a></li><li><a class="nounderline abstract_t">Büchner M, Dostert S, Falkert A, et al. Perinatal diagnosis of a lymphedema-distichiasis syndrome (LD). Prenat Diagn 2007; 27:1069.</a></li><li><a class="nounderline abstract_t">Quinn AM, Valcarcel BN, Makhamreh MM, et al. A systematic review of monogenic etiologies of nonimmune hydrops fetalis. Genet Med 2021; 23:3.</a></li><li><a class="nounderline abstract_t">McPherson E. Hydrops fetalis in a cohort of 3,137 stillbirths and second trimester miscarriages. Am J Med Genet A 2019; 179:2338.</a></li><li><a class="nounderline abstract_t">Brewer CJ, Makhamreh MM, Shivashankar K, et al. PIEZO1 is the most common monogenic etiology of non-immune hydrops fetalis detected by prenatal exome sequencing. Prenat Diagn 2023; 43:1556.</a></li><li><a class="nounderline abstract_t">Xu J, Raff TC, Muallem NS, Neubert AG. Hydrops fetalis secondary to parvovirus B19 infections. J Am Board Fam Pract 2003; 16:63.</a></li><li><a class="nounderline abstract_t">Barron SD, Pass RF. Infectious causes of hydrops fetalis. Semin Perinatol 1995; 19:493.</a></li><li><a class="nounderline abstract_t">von Kaisenberg CS, Jonat W. Fetal parvovirus B19 infection. Ultrasound Obstet Gynecol 2001; 18:280.</a></li><li><a class="nounderline abstract_t">Yinon Y, Grisaru-Granovsky S, Chaddha V, et al. Perinatal outcome following fetal chest shunt insertion for pleural effusion. Ultrasound Obstet Gynecol 2010; 36:58.</a></li><li><a class="nounderline abstract_t">Wada S, Jwa SC, Yumoto Y, et al. The prognostic factors and outcomes of primary fetal hydrothorax with the effects of fetal intervention. Prenat Diagn 2017; 37:184.</a></li><li><a class="nounderline abstract_t">Rustico MA, Lanna M, Coviello D, et al. Fetal pleural effusion. Prenat Diagn 2007; 27:793.</a></li><li><a class="nounderline abstract_t">Wellesley D, Howe DT. Diagnosis and outcome in nonhydropic fetal pleural effusions. Prenat Diagn 2018; 38:866.</a></li><li><a class="nounderline abstract_t">Stevenson DA, Pysher TJ, Ward RM, Carey JC. Familial congenital non-immune hydrops, chylothorax, and pulmonary lymphangiectasia. Am J Med Genet A 2006; 140:368.</a></li><li><a class="nounderline abstract_t">Reiterer F, Grossauer K, Morris N, et al. Congenital pulmonary lymphangiectasis. Paediatr Respir Rev 2014; 15:275.</a></li><li><a class="nounderline abstract_t">Toru HS, Sanhal CY, Yilmaz GT, et al. Rare congenital pulmonary malformation with diagnostic challenging: congenital pulmonary lymphangiectasia, report of four autopsy cases and review of literature. J Matern Fetal Neonatal Med 2015; 28:1457.</a></li><li><a class="nounderline abstract_t">Wieacker P, Muschke P, Pollak KH, Müller R. Autosomal recessive non-immune hydrops fetalis caused by systemic lymphangiectasia. Am J Med Genet A 2005; 132A:318.</a></li><li><a class="nounderline abstract_t">Deurloo KL, Devlieger R, Lopriore E, et al. Isolated fetal hydrothorax with hydrops: a systematic review of prenatal treatment options. Prenat Diagn 2007; 27:893.</a></li><li><a class="nounderline abstract_t">Picone O, Benachi A, Mandelbrot L, et al. Thoracoamniotic shunting for fetal pleural effusions with hydrops. Am J Obstet Gynecol 2004; 191:2047.</a></li><li><a class="nounderline abstract_t">Pellegrinelli JM, Kohler A, Kohler M, et al. Prenatal management and thoracoamniotic shunting in primary fetal pleural effusions: a single centre experience. Prenat Diagn 2012; 32:467.</a></li><li><a class="nounderline abstract_t">Aubard Y, Derouineau I, Aubard V, et al. Primary fetal hydrothorax: A literature review and proposed antenatal clinical strategy. Fetal Diagn Ther 1998; 13:325.</a></li><li><a class="nounderline abstract_t">Yang YS, Ma GC, Shih JC, et al. Experimental treatment of bilateral fetal chylothorax using in-utero pleurodesis. Ultrasound Obstet Gynecol 2012; 39:56.</a></li><li><a class="nounderline abstract_t">Buca D, Iacovella C, Khalil A, et al. Perinatal outcome of pregnancies complicated by placental chorioangioma: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2020; 55:441.</a></li><li><a class="nounderline abstract_t">Sepulveda W, Wong AE, Herrera L, et al. Endoscopic laser coagulation of feeding vessels in large placental chorioangiomas: report of three cases and review of invasive treatment options. Prenat Diagn 2009; 29:201.</a></li><li><a class="nounderline abstract_t">Hamouda S, Soussan J, Haumonté JB, Bretelle F. In utero embolization for placental chorioangioma and neonatal multifocal hemangiomatosis. J Gynecol Obstet Hum Reprod 2019; 48:689.</a></li><li><a class="nounderline abstract_t">Mathis J, Raio L, Baud D. Fetal laser therapy: applications in the management of fetal pathologies. Prenat Diagn 2015; 35:623.</a></li><li><a class="nounderline abstract_t">Jhun KM, Nassar P, Chen TS, et al. Giant chorioangioma treated in utero via laser of feeding vessels with subsequent development of multifocal infantile hemangiomas. Fetal Pediatr Pathol 2015; 34:1.</a></li><li><a class="nounderline abstract_t">Cheng YK, Yu SC, So PL, Leung TY. Ultrasound-Guided Percutaneous Embolisation of Placental Chorioangioma Using Cyanoacrylate. Fetal Diagn Ther 2017; 41:76.</a></li><li><a class="nounderline abstract_t">Sanz Cortes M, Bechtold H, Qureshi AM, et al. Innovation in fetal surgery: Use of vascular plugs in placental chorioangioma with fetal hydrops. Prenat Diagn 2022; 42:1471.</a></li><li><a class="nounderline abstract_t">Gimovsky AC, Luzi P, Berghella V. Lysosomal storage disease as an etiology of nonimmune hydrops. Am J Obstet Gynecol 2015; 212:281.</a></li><li><a class="nounderline abstract_t">Al-Kouatly HB, Felder L, Makhamreh MM, et al. Lysosomal storage disease spectrum in nonimmune hydrops fetalis: a retrospective case control study. Prenat Diagn 2020; 40:738.</a></li><li><a class="nounderline abstract_t">Wraith JE. Lysosomal disorders. Semin Neonatol 2002; 7:75.</a></li><li><a class="nounderline abstract_t">Gort L, Granell MR, Fernández G, et al. Fast protocol for the diagnosis of lysosomal diseases in nonimmune hydrops fetalis. Prenat Diagn 2012; 32:1139.</a></li><li><a class="nounderline abstract_t">Heinonen S, Ryynänen M, Kirkinen P. Etiology and outcome of second trimester non-immunologic fetal hydrops. Acta Obstet Gynecol Scand 2000; 79:15.</a></li><li><a class="nounderline abstract_t">Wy CA, Sajous CH, Loberiza F, Weiss MG. Outcome of infants with a diagnosis of hydrops fetalis in the 1990s. Am J Perinatol 1999; 16:561.</a></li><li><a class="nounderline abstract_t">Santo S, Mansour S, Thilaganathan B, et al. Prenatal diagnosis of non-immune hydrops fetalis: what do we tell the parents? Prenat Diagn 2011; 31:186.</a></li><li><a class="nounderline abstract_t">Iskaros J, Jauniaux E, Rodeck C. Outcome of nonimmune hydrops fetalis diagnosed during the first half of pregnancy. Obstet Gynecol 1997; 90:321.</a></li><li><a class="nounderline abstract_t">Tulzer G, Gudmundsson S, Wood DC, et al. Doppler in non-immune hydrops fetalis. Ultrasound Obstet Gynecol 1994; 4:279.</a></li><li><a class="nounderline abstract_t">Mascaretti RS, Falcão MC, Silva AM, et al. Characterization of newborns with nonimmune hydrops fetalis admitted to a neonatal intensive care unit. Rev Hosp Clin Fac Med Sao Paulo 2003; 58:125.</a></li><li><a class="nounderline abstract_t">Huang HR, Tsay PK, Chiang MC, et al. Prognostic factors and clinical features in liveborn neonates with hydrops fetalis. Am J Perinatol 2007; 24:33.</a></li><li><a class="nounderline abstract_t">Moldenhauer JS. Ex Utero Intrapartum Therapy. Semin Pediatr Surg 2013; 22:44.</a></li><li><a class="nounderline abstract_t">Shamshirsaz AA, Aalipour S, Erfani H, et al. Obstetric outcomes of ex-utero intrapartum treatment (EXIT). Prenat Diagn 2019; 39:643.</a></li><li><a class="nounderline abstract_t">Novoa RH, Quintana W, Castillo-Urquiaga W, Ventura W. EXIT (ex utero intrapartum treatment) surgery for the management of fetal airway obstruction: A systematic review of the literature. J Pediatr Surg 2020; 55:1188.</a></li><li><a class="nounderline abstract_t">Désilets V, Audibert F, Society of Obstetrician and Gynaecologists of Canada. Investigation and management of non-immune fetal hydrops. J Obstet Gynaecol Can 2013; 35:923.</a></li><li><a class="nounderline abstract_t">Wagner T, Fahham D, Frumkin A, et al. The many etiologies of nonimmune hydrops fetalis diagnosed by exome sequencing. Prenat Diagn 2022; 42:881.</a></li><li><a class="nounderline abstract_t">Schwartz SM, Viseskul C, Laxova R, et al. Idiopathic hydrops fetalis report of 4 patients including 2 affected sibs. Am J Med Genet 1981; 8:59.</a></li><li><a class="nounderline abstract_t">Cumming DC. Recurrent nonimmune hydrops fetalis. Obstet Gynecol 1979; 54:124.</a></li><li><a class="nounderline abstract_t">Etches PC, Lemons JA. Nonimmune hydrops fetalis: report of 22 cases including three siblings. Pediatrics 1979; 64:326.</a></li></ol></div><div id="topicVersionRevision">Topic 6794 Version 63.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11531615" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Analysis of outcome in hydrops fetalis in relation to gestational age at diagnosis, cause and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2256483" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prognostic indicators of the resolution of nonimmune hydrops fetalis and survival of the fetus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3532802" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Nonimmune hydrops fetalis: clinical experience and factors related to a poor outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3532802" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Nonimmune hydrops fetalis: clinical experience and factors related to a poor outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8915090" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Management of non-immune hydrops: 8 years' experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28533037" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Epidemiology of Live Born Infants with Nonimmune Hydrops Fetalis-Insights from a Population-Based Dataset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1298071" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Thalassemia in SouthEast Asia: problems and strategy for prevention and control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22302731" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Non-immune hydrops fetalis: a short review of etiology and pathophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8822329" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Nonimmune fetal hydrops: diagnosis and obstetrical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34735407" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Etiology and Outcome of Isolated Fetal Ascites: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22249145" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prenatal diagnosis of pulmonary hypoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9397111" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A prospective evaluation of fetal pericardial fluid in 506 second-trimester low-risk pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7932994" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical significance of isolated fetal pericardial effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30048635" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : SMFM Consult Series #46: Evaluation and management of polyhydramnios.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8822334" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hematologic disorders and nonimmune hydrops fetalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3126469" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The role of sonography in assessing severity of fetal anemia in Rh- and Kell-isoimmunized pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7291522" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Nonimmunologic fetal hydrops wtih theca lutein cysts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3314519" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Theca-lutein ovarian cysts associated with homozygous alpha-thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3883269" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Nonimmunologic fetal hydrops associated with hyperreactio luteinalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10679701" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Early prenatal sonographic diagnosis of twin triploid gestation presenting with fetal hydrops and theca-lutein ovarian cysts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12186993" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Hyperreactio luteinalis associated with severe twin-to-twin transfusion syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16641410" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Elevated sFlt1 level and preeclampsia with parvovirus-induced hydrops.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12442609" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A case of peripartum cardiomyopathy with a transient increase of plasma interleukin-6 concentration occurred following mirror syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12380459" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mirror syndrome. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1780115" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Maternal hydrops syndrome: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37385374" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Mirror syndrome: a systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20357423" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Mirror syndrome: a systematic review of fetal associated conditions, maternal presentation and perinatal outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10804498" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Reversal of Ballantyne syndrome by selective second-trimester fetal termination. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15294378" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Spontaneous reversal of mirror syndrome in a twin pregnancy after a single fetal death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17666658" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Mirror syndrome: a novel approach to therapy with fetal peritoneal-amniotic shunt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25614410" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Reversal of mirror syndrome after selective feticide of a hydropic fetus in a dichorionic diamniotic twin pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23711762" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Normalisation of angiogenic imbalance after intra-uterine transfusion for mirror syndrome caused by parvovirus B19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25557883" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Society for maternal-fetal medicine (SMFM) clinical guideline #7: nonimmune hydrops fetalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19334091" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Etiology of nonimmune hydrops fetalis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10620643" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19582828" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Middle cerebral artery peak systolic velocity and ductus venosus velocity in the investigation of nonimmune hydrops.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11444786" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Etiology and outcome of hydrops fetalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6702918" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Nonimmune hydrops fetalis: antenatal diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31981373" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Utility of chromosomal microarray for diagnosis in cases of nonimmune hydrops fetalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31087399" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A system-based approach to the genetic etiologies of non-immune hydrops fetalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34331894" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Exome sequencing vs targeted gene panels for the evaluation of nonimmune hydrops fetalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33847422" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Fetal hydrops and the Incremental yield of Next-generation sequencing over standard prenatal Diagnostic testing (FIND) study: prospective cohort study and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7898837" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Non-immune hydrops after 20 weeks' gestation: review of 10 years' experience with suggestions for management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26223439" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Inherited metabolic disorders: prenatal diagnosis of lysosomal storage disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9155679" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Mucopolysaccharidosis type VII associated with hydrops fetalis: histopathological and ultrastructural features with genetic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15305357" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Investigation of lysosomal storage diseases in nonimmune hydrops fetalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25346315" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Biochemical analysis of ascites fluid as an aid to etiological diagnosis: a series of 100 cases of nonimmune fetal ascites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9917489" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Congenital hypothyroidism and nonimmune hydrops fetalis: associated?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10441620" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Investigation of nonimmune hydrops fetalis: multidisciplinary studies are necessary for diagnosis--review of 94 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9027912" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Hydrops fetalis: recent advances.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32196790" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Non-immune fetal hydrops: etiology and outcome according to gestational age at diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20721876" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Fetal cardiac tumors: a single-center experience of 40 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27530489" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Fetal intrapericardial teratoma: natural history and management including successful in utero surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26886784" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Fetal interventions for congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3407692" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Prenatal detection of congenital heart disease: factors affecting obstetric management and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3407692" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Prenatal detection of congenital heart disease: factors affecting obstetric management and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9086526" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Management of fetal cardiac arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2688420" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Hydrops revisited: literature review of 1,414 cases published in the 1980s.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20160425" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Transient abnormal myelopoiesis associated with Down syndrome presenting as severe hydrops fetalis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29500832" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Improved diagnosis in nonimmune hydrops fetalis using a standardized algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/508920" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Prenatal detection of a familial nuchal bleb simulating encephalocele.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9098491" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Elejalde syndrome: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17369693" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Prenatal and postnatal management of a patient with pentalogy of Cantrell and left ventricular aneurysm. A case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17721865" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Perinatal diagnosis of a lymphedema-distichiasis syndrome (LD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33082562" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A systematic review of monogenic etiologies of nonimmune hydrops fetalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31512356" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Hydrops fetalis in a cohort of 3,137 stillbirths and second trimester miscarriages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37902181" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : PIEZO1 is the most common monogenic etiology of non-immune hydrops fetalis detected by prenatal exome sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12583652" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Hydrops fetalis secondary to parvovirus B19 infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8822333" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Infectious causes of hydrops fetalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11555463" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Fetal parvovirus B19 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20069656" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Perinatal outcome following fetal chest shunt insertion for pleural effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27977046" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The prognostic factors and outcomes of primary fetal hydrothorax with the effects of fetal intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17602440" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Fetal pleural effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30095865" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Diagnosis and outcome in nonhydropic fetal pleural effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16419129" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Familial congenital non-immune hydrops, chylothorax, and pulmonary lymphangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24997116" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Congenital pulmonary lymphangiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25142108" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Rare congenital pulmonary malformation with diagnostic challenging: congenital pulmonary lymphangiectasia, report of four autopsy cases and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15690379" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Autosomal recessive non-immune hydrops fetalis caused by systemic lymphangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17605152" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Isolated fetal hydrothorax with hydrops: a systematic review of prenatal treatment options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15592290" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Thoracoamniotic shunting for fetal pleural effusions with hydrops.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22499187" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Prenatal management and thoracoamniotic shunting in primary fetal pleural effusions: a single centre experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9933813" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Primary fetal hydrothorax: A literature review and proposed antenatal clinical strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21584887" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Experimental treatment of bilateral fetal chylothorax using in-utero pleurodesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31034661" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Perinatal outcome of pregnancies complicated by placental chorioangioma: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19156708" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Endoscopic laser coagulation of feeding vessels in large placental chorioangiomas: report of three cases and review of invasive treatment options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31112760" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : In utero embolization for placental chorioangioma and neonatal multifocal hemangiomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25736523" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Fetal laser therapy: applications in the management of fetal pathologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24941233" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Giant chorioangioma treated in utero via laser of feeding vessels with subsequent development of multifocal infantile hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26727372" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Ultrasound-Guided Percutaneous Embolisation of Placental Chorioangioma Using Cyanoacrylate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35986587" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Innovation in fetal surgery: Use of vascular plugs in placental chorioangioma with fetal hydrops.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25305402" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Lysosomal storage disease as an etiology of nonimmune hydrops.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32134517" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Lysosomal storage disease spectrum in nonimmune hydrops fetalis: a retrospective case control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12069540" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Lysosomal disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22991067" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Fast protocol for the diagnosis of lysosomal diseases in nonimmune hydrops fetalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10646810" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Etiology and outcome of second trimester non-immunologic fetal hydrops.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10874994" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Outcome of infants with a diagnosis of hydrops fetalis in the 1990s.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21268039" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Prenatal diagnosis of non-immune hydrops fetalis: what do we tell the parents?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9277637" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Outcome of nonimmune hydrops fetalis diagnosed during the first half of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12797161" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Doppler in non-immune hydrops fetalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12894308" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Characterization of newborns with nonimmune hydrops fetalis admitted to a neonatal intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17195148" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Prognostic factors and clinical features in liveborn neonates with hydrops fetalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23395145" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Ex Utero Intrapartum Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31093996" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Obstetric outcomes of ex-utero intrapartum treatment (EXIT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32151401" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : EXIT (ex utero intrapartum treatment) surgery for the management of fetal airway obstruction: A systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24165062" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Investigation and management of non-immune fetal hydrops.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34132406" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : The many etiologies of nonimmune hydrops fetalis diagnosed by exome sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7018238" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Idiopathic hydrops fetalis report of 4 patients including 2 affected sibs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/377163" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Recurrent nonimmune hydrops fetalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/481978" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Nonimmune hydrops fetalis: report of 22 cases including three siblings.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
